Psyence BioMed Welcomes U.S. Executive Order on Ibogaine Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy PBM?
Source: Newsfilter
- Executive Order Impact: Psyence BioMed acknowledges the U.S. administration's preparation of an executive order to evaluate ibogaine's safety and therapeutic potential, reflecting a growing emphasis on rigorous research into novel therapies, which may advance the company's clinical research in PTSD and addiction.
- CEO Statement: CEO Jody Aufrichtig expressed support for structured, evidence-based research to clarify ibogaine's safety and efficacy, which will enhance patient safety and long-term access, thereby strengthening the company's competitive position in the biopharmaceutical sector.
- GMP Manufacturing Advantage: Through strategic investment in PsyLabs, Psyence BioMed has established a leading position in GMP-compliant manufacturing of ibogaine, supporting global clinical research and future therapeutic development while ensuring product quality and traceability.
- Ethical Sourcing Strategy: The company is committed to developing a responsible and ethical ibogaine supply chain that ensures sustainability and respects traditional practices, positioning Psyence BioMed's integrated platform to support the next phase of research and potential regulatory evolution as global interest in ibogaine accelerates.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBM
About PBM
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Signs Order to Accelerate Psychedelic Drug Research
- Policy Driving Research: President Trump signed an executive order directing health regulators to expedite reviews of psychedelic drugs and increase federal funding, responding to advocates like Joe Rogan, indicating a governmental acknowledgment of the potential medical uses of psychedelics.
- Clinical Trial Progress: Current trials show strong evidence for the use of psychedelics in treating severe depression and PTSD, particularly in patients unresponsive to existing treatments, suggesting these drugs could become viable new therapeutic options.
- Drug Authorization Status: In the U.S., Johnson & Johnson's esketamine nasal spray is approved for treatment-resistant depression, while countries like Australia and Switzerland have authorized psilocybin and MDMA for various uses, reflecting a global recognition of the therapeutic potential of psychedelics.
- Risk Assessment: Despite the therapeutic promise of psychedelics, risks such as acute anxiety and confusion during administration, as well as higher risks when used outside clinical settings, highlight the need for caution in their research and application.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Policy Catalyst: Trump's executive order directs the FDA to expedite the review of psychedelic drugs and commits $50 million to related clinical research, which is expected to significantly enhance market recognition and attract investment in psychedelic therapies.
- Inventory Advantage: Psyence Biomedical currently holds standardized, stabilized GMP-compliant ibogaine doses, addressing the scarcity of clinical-grade materials in the market, which is likely to strengthen its competitive position in the psychedelic drug sector.
- Vertical Integration: Through its investment in PsyLabs, Psyence has established a vertically integrated platform that spans sourcing in Africa, extraction, purification, and pharmaceutical production, effectively reducing supply chain delays and accelerating progress in ibogaine-based clinical research.
- Surging Market Sentiment: PBM shares surged 182% over the past three days, with retail sentiment on Stocktwits being extremely bullish, indicating strong market confidence in the company's future, which may attract more investors to the psychedelic drug market.
See More
AtaiBeckley Price Target Raised to $15 Amid Positive Drug Trial News
- Price Target Increase: Canaccord analyst Sumant Kulkarni raised AtaiBeckley's price target from $14 to $15 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance.
- Clinical Trial Progress: Atai is preparing for its investigational psychedelic drug BPL-003 to enter late-stage trials this quarter, which is designed for treatment-resistant depression and is expected to significantly enhance the company's market position in this sector.
- Positive Market Reaction: Following President Trump's executive order to expedite psychedelic drug research, AtaiBeckley shares surged 28% on Monday, potentially marking the best single-day gain, reflecting growing optimism in the psychedelic drug industry.
- Analyst Consensus: According to Koyfin data, all 14 analysts covering ATAI rate it 'Buy' or higher, with a 12-month average price target of $13.83, representing a potential upside of about 166% from current trading levels.
See More
Trump Accelerates Psychedelic Research, PBM Stock Soars
- Policy-Driven Funding: Trump signed an executive order directing the FDA to expedite reviews of psychedelic medicines while committing $50 million for clinical research, providing robust policy support for the legalization and application of psychedelics.
- Stock Surge Performance: Following Trump's announcement, Psyence Biomedical (PBM) shares surged over 111% in premarket trading on Monday and achieved a remarkable 185% increase last week, indicating strong market performance and renewed investor confidence in the psychedelic sector.
- Production Capacity Enhancement: Psyence has established a GMP-compliant platform for producing medical-grade ibogaine, ensuring its application in clinical research and drug development, and has sourced high-purity ibogaine hydrochloride from Africa, showcasing its competitive edge in the global market.
- Market Sentiment Extremely Bullish: Retail sentiment for PBM on Stocktwits has remained extremely bullish, with message volumes surging 15,100% over the past month, reflecting strong market expectations and confidence in PBM's future, particularly regarding the potential demand for psychedelic therapies.
See More
U.S. Stock Futures Retreat Amid Renewed Geopolitical Tensions
- Futures Pullback: U.S. stock futures retreated early Monday after last week's record highs, with S&P 500 and Nasdaq futures down 0.6% and 0.7% respectively, indicating rising investor concerns over geopolitical risks.
- Strait of Hormuz Tensions: Iran's announcement to keep the critical shipping route restricted, coupled with President Trump's confirmation of seizing an Iranian cargo ship, has reignited market focus on oil price volatility, prompting renewed interest in oil-linked stocks like BATL and EONR.
- Psychedelic Stocks Surge: Following President Trump's executive order to expedite psychedelic drug approvals, stocks like Psyence Biomedical (PBM), Definium Therapeutics (DFTX), and Compass Pathways (CMPS) are gaining retail investor attention, reflecting a growing market interest in mental health treatments.
- Tesla's Positive Outlook: Tesla is on track for its first positive month this year, with Elon Musk downplaying competitive fears from China's BYD, emphasizing that execution, rather than competition, is the key challenge for the EV maker, showcasing the company's confidence in its future performance.
See More
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
- Psychedelic Research Advancement: The Trump administration is drafting an executive order indicating a willingness to further investigate the safety and efficacy of ibogaine, a psychedelic used for treating PTSD, which is expected to accelerate clinical research in this area.
- Positive Market Reaction: Following the announcement, stocks of companies like Clearmind Medicine (CMND), Atai Beckley (ATAI), and Cybin (HELP) rose, reflecting market optimism regarding the potential applications of psychedelics in mental health treatment.
- Strait of Hormuz Passage Statement: Iran's Foreign Minister declared that commercial vessels can fully pass through the Strait of Hormuz during the ceasefire in Lebanon, while Trump confirmed normal passage but maintained a naval blockade against Iran, highlighting the complexities of geopolitical tensions in the region.
- AI Model Utilization: The U.S. government is preparing to make Anthropic PBC's AI model Mythos available to major federal agencies despite cybersecurity risks, indicating a balancing act between promoting technological innovation and ensuring data security.
See More
Trump Signs Order to Accelerate Psychedelic Drug Research
- Policy Driving Research: President Trump signed an executive order directing health regulators to expedite reviews of psychedelic drugs and increase federal funding, responding to advocates like Joe Rogan, indicating a governmental acknowledgment of the potential medical uses of psychedelics.
- Clinical Trial Progress: Current trials show strong evidence for the use of psychedelics in treating severe depression and PTSD, particularly in patients unresponsive to existing treatments, suggesting these drugs could become viable new therapeutic options.
- Drug Authorization Status: In the U.S., Johnson & Johnson's esketamine nasal spray is approved for treatment-resistant depression, while countries like Australia and Switzerland have authorized psilocybin and MDMA for various uses, reflecting a global recognition of the therapeutic potential of psychedelics.
- Risk Assessment: Despite the therapeutic promise of psychedelics, risks such as acute anxiety and confusion during administration, as well as higher risks when used outside clinical settings, highlight the need for caution in their research and application.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Policy Catalyst: Trump's executive order directs the FDA to expedite the review of psychedelic drugs and commits $50 million to related clinical research, which is expected to significantly enhance market recognition and attract investment in psychedelic therapies.
- Inventory Advantage: Psyence Biomedical currently holds standardized, stabilized GMP-compliant ibogaine doses, addressing the scarcity of clinical-grade materials in the market, which is likely to strengthen its competitive position in the psychedelic drug sector.
- Vertical Integration: Through its investment in PsyLabs, Psyence has established a vertically integrated platform that spans sourcing in Africa, extraction, purification, and pharmaceutical production, effectively reducing supply chain delays and accelerating progress in ibogaine-based clinical research.
- Surging Market Sentiment: PBM shares surged 182% over the past three days, with retail sentiment on Stocktwits being extremely bullish, indicating strong market confidence in the company's future, which may attract more investors to the psychedelic drug market.
See More
AtaiBeckley Price Target Raised to $15 Amid Positive Drug Trial News
- Price Target Increase: Canaccord analyst Sumant Kulkarni raised AtaiBeckley's price target from $14 to $15 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance.
- Clinical Trial Progress: Atai is preparing for its investigational psychedelic drug BPL-003 to enter late-stage trials this quarter, which is designed for treatment-resistant depression and is expected to significantly enhance the company's market position in this sector.
- Positive Market Reaction: Following President Trump's executive order to expedite psychedelic drug research, AtaiBeckley shares surged 28% on Monday, potentially marking the best single-day gain, reflecting growing optimism in the psychedelic drug industry.
- Analyst Consensus: According to Koyfin data, all 14 analysts covering ATAI rate it 'Buy' or higher, with a 12-month average price target of $13.83, representing a potential upside of about 166% from current trading levels.
See More
Trump Accelerates Psychedelic Research, PBM Stock Soars
- Policy-Driven Funding: Trump signed an executive order directing the FDA to expedite reviews of psychedelic medicines while committing $50 million for clinical research, providing robust policy support for the legalization and application of psychedelics.
- Stock Surge Performance: Following Trump's announcement, Psyence Biomedical (PBM) shares surged over 111% in premarket trading on Monday and achieved a remarkable 185% increase last week, indicating strong market performance and renewed investor confidence in the psychedelic sector.
- Production Capacity Enhancement: Psyence has established a GMP-compliant platform for producing medical-grade ibogaine, ensuring its application in clinical research and drug development, and has sourced high-purity ibogaine hydrochloride from Africa, showcasing its competitive edge in the global market.
- Market Sentiment Extremely Bullish: Retail sentiment for PBM on Stocktwits has remained extremely bullish, with message volumes surging 15,100% over the past month, reflecting strong market expectations and confidence in PBM's future, particularly regarding the potential demand for psychedelic therapies.
See More
U.S. Stock Futures Retreat Amid Renewed Geopolitical Tensions
- Futures Pullback: U.S. stock futures retreated early Monday after last week's record highs, with S&P 500 and Nasdaq futures down 0.6% and 0.7% respectively, indicating rising investor concerns over geopolitical risks.
- Strait of Hormuz Tensions: Iran's announcement to keep the critical shipping route restricted, coupled with President Trump's confirmation of seizing an Iranian cargo ship, has reignited market focus on oil price volatility, prompting renewed interest in oil-linked stocks like BATL and EONR.
- Psychedelic Stocks Surge: Following President Trump's executive order to expedite psychedelic drug approvals, stocks like Psyence Biomedical (PBM), Definium Therapeutics (DFTX), and Compass Pathways (CMPS) are gaining retail investor attention, reflecting a growing market interest in mental health treatments.
- Tesla's Positive Outlook: Tesla is on track for its first positive month this year, with Elon Musk downplaying competitive fears from China's BYD, emphasizing that execution, rather than competition, is the key challenge for the EV maker, showcasing the company's confidence in its future performance.
See More
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
- Psychedelic Research Advancement: The Trump administration is drafting an executive order indicating a willingness to further investigate the safety and efficacy of ibogaine, a psychedelic used for treating PTSD, which is expected to accelerate clinical research in this area.
- Positive Market Reaction: Following the announcement, stocks of companies like Clearmind Medicine (CMND), Atai Beckley (ATAI), and Cybin (HELP) rose, reflecting market optimism regarding the potential applications of psychedelics in mental health treatment.
- Strait of Hormuz Passage Statement: Iran's Foreign Minister declared that commercial vessels can fully pass through the Strait of Hormuz during the ceasefire in Lebanon, while Trump confirmed normal passage but maintained a naval blockade against Iran, highlighting the complexities of geopolitical tensions in the region.
- AI Model Utilization: The U.S. government is preparing to make Anthropic PBC's AI model Mythos available to major federal agencies despite cybersecurity risks, indicating a balancing act between promoting technological innovation and ensuring data security.
See More
